Press Releases
April 17‚ 2008
Anthera presents data on Varespladib at ATVB meeting
February 7‚ 2008
Data From Anthera's PLASMA Trial to be Presented as Late Breaker at American College of Cardiology Scientific Sessions
February 5‚ 2008
Anthera Pharmaceuticals Forms Scientific Advisory Board
January 31‚ 2008
Anthera enters into manufacturing agreements for varespladib in preparation for pivotal Phase III trials.
January 15‚ 2008
Anthera Announces Preliminary Positive Results from Once-Daily A-002 Phase II Cardiovascular Trial.
January 8‚ 2008
Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases.
December 18‚ 2007
Anthera’s A-001 Receives orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease.
December 06‚ 2007
Anthera Pharmaceuticals names Christopher P. Lowe Chief Financial Officer.
October 30‚ 2007
Anthera Pharmaceuticals, Inc. appoints Donald Santel to Board of Directors.
October 24‚ 2007
Anthera announces Positive Phase II clinical results from A-002 cardiovascular disease trial.
October 3‚ 2007
Anthera announces completion of enrollment and dosing in Phase II trial of A-002 for the treatment of cardiovascular disease trial.
July 2‚ 2007
Anthera Completes Enrollment of "PLASMA" Trial with A-002 and Announces Initiation of New Investigator Study
April 13‚ 2007
First Patient Enrolled In Phase 2 "PLASMA" Trial with A-002 for Patients with Coronary Atherosclerosis
March 20‚ 2007
Anthera Pharmaceuticals‚ Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer
March 8‚ 2007
Anthera Pharmaceuticals‚ Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
February 13‚ 2007
Anthera Pharmaceuticals‚ Inc. Announces Formation of Clinical Advisory Board for CARDIOVASCULAR Program
February 7‚ 2007
Dr. David D. Waters Joins Anthera Pharmaceuticals as Cardiovascular Research Fellow
January 4‚ 2007
Anthera Receives FDA Approval to begin phase 2 “PLASMA” trial with a-002 For patients with coronary atherosclerosis
September 13‚ 2006
Anthera Pharmaceuticals Secures $36M Venture Financing To Initiate Clinical Programs
September 06‚ 2006
Anthera Licenses Portfolio of Anti–Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.
November 17‚ 2005
Anthera Pharmaceuticals Appoints David E. Thompson To Board Of Directors
April 20‚ 2005
Anthera Pharmaceuticals Launches With A Proven Leadership Team And Significant Series A Funding